NCT06563648

Brief Summary

The research was conducted as a single-blind, randomized controlled, experimental study to determine the effect of ShotBlocker and local cold application on pain and patient satisfaction in subcutaneous heparin injection.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
208

participants targeted

Target at P75+ for not_applicable pain

Timeline
Completed

Started Jan 2022

Typical duration for not_applicable pain

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2022

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2023

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2024

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

August 12, 2024

Completed
9 days until next milestone

First Posted

Study publicly available on registry

August 21, 2024

Completed
Last Updated

August 21, 2024

Status Verified

August 1, 2024

Enrollment Period

2 years

First QC Date

August 12, 2024

Last Update Submit

August 19, 2024

Conditions

Keywords

Subcutaneous injectionshotblockercold applicationlow molecular weight heparinpainsatisfaction

Outcome Measures

Primary Outcomes (1)

  • Visual analog scale

    The VAS is used to assess the severity of acute pain. It is mostly a horizontal or vertical line 100 mm long, starting with "no pain" and ending with "unbearable pain". It is used to convert some values that cannot be measured numerically to a numerically usable form

    At the first minute after the injection, the patients were evaluated about the pain they felt during the injection by a different reseacher.

Secondary Outcomes (1)

  • Visual patient satisfaction scale

    At the first minute after the injection, the patients were evaluated their satisfaction with the injection by a different reseacher.

Study Arms (4)

ShotBlocker group

EXPERIMENTAL

A ShotBlocker was placed on the arm of the patients in the ShotBlocker group during the injection, and the injection was performed from the part where the opening was located by lightly pressing with the fingertips throughout the injection.

Other: shotblocker

ShotBlocker placebo group

EXPERIMENTAL

During the injection, the back side of the ShotBlocker was placed on the arm of the patients in the ShotBlocker placebo group and the injection was performed by gently pressing with the fingertips throughout the injection.

Other: ShotBlocker placebo group

Local cold application group

EXPERIMENTAL

Local cold application was applied to the arm of the patients in the local cold application group for five minutes using a cold pack,and then the injection was performed.

Other: local cold application

control group

NO INTERVENTION

Patients in the control group were injected with a routine subcutaneous injection procedure.

Interventions

A ShotBlocker was placed on the arm of the patients in the ShotBlocker group during the injection, and the injection was performed from the part where the opening was located by lightly pressing with the fingertips throughout the injection.

ShotBlocker group

Local cold application was applied to the arm of the patients in the local cold application group for five minutes using a cold pack, and then the injection was performed.

Local cold application group

During the injection, the back side of the ShotBlocker was placed on the arm of the patients in the ShotBlocker placebo group and the injection was performed by gently pressing with the fingertips throughout the injection.

ShotBlocker placebo group

Eligibility Criteria

Age18 Years - 95 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Enoxaparin sodium 1x1 0.6 ml. SC treatment
  • Over 18 years of age
  • No vision or hearing problems
  • No scar tissue, incision, lipodystrophy or infection at the injection site

You may not qualify if:

  • Underwent mastectomy
  • Not being voluntering

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ege university nursing faculty

Izmir, Bornova, 35360, Turkey (Türkiye)

Location

Related Publications (3)

  • Usach I, Martinez R, Festini T, Peris JE. Subcutaneous Injection of Drugs: Literature Review of Factors Influencing Pain Sensation at the Injection Site. Adv Ther. 2019 Nov;36(11):2986-2996. doi: 10.1007/s12325-019-01101-6. Epub 2019 Oct 5.

    PMID: 31587143BACKGROUND
  • Wang H, Guan J, Zhang X, Wang X, Ji T, Hou D, Wang G, Sun J. Effect of Cold Application on Pain and Bruising in Patients With Subcutaneous Injection of Low-Molecular-Weight Heparin: A Meta-Analysis. Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620905349. doi: 10.1177/1076029620905349.

    PMID: 32372652BACKGROUND
  • Woodley WD, Morel DR, Sutter DE, Pettis RJ, Bolick NG. Clinical evaluation of large volume subcutaneous injection tissue effects, pain, and acceptability in healthy adults. Clin Transl Sci. 2022 Jan;15(1):92-104. doi: 10.1111/cts.13109. Epub 2021 Nov 10.

    PMID: 34268888BACKGROUND

MeSH Terms

Conditions

PainPatient SatisfactionPersonal Satisfaction

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsTreatment Adherence and ComplianceHealth BehaviorBehavior

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
PREVENTION
Intervention Model
FACTORIAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
research assistant faculty of nursing principles

Study Record Dates

First Submitted

August 12, 2024

First Posted

August 21, 2024

Study Start

January 1, 2022

Primary Completion

December 31, 2023

Study Completion

April 30, 2024

Last Updated

August 21, 2024

Record last verified: 2024-08

Locations